Ågot Högberg
AstraZeneca
3 Papers
30 Citations
Ågot Högberg is an academic researcher from AstraZeneca. The author has contributed to research in topics: Lactam & Acetamide. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Isoindolinone compounds active as Kv1.5 blockers identified using a multicomponent reaction approach.
Johan Kajanus,Ingemar Jacobson,Annika Åstrand,Roine I. Olsson,Ulrik Gran,Annika Björe,Ola Fjellström,Öjvind Davidsson,Hans Emtenäs,Anders Dahlén,Boel Löfberg,Zhong-Qing Yuan,Johan Sundell,Johan Cassel,Jonna Gyll,Tommy Iliefski,Ågot Högberg,Emma Lindhardt,Jesper Malmberg +18 more
TL;DR: By modification of two side chains on the isoindolinone scaffold, metabolically stable compounds with good in vivo PK profile could be obtained leaving the core structure unsubstituted, and low microsomal intrinsic clearance (CLint) could be achieved despite a relatively high logD.
17
Lactam sulfonamides as potent inhibitors of the Kv1.5 potassium ion channel
Roine I. Olsson,Ingemar Jacobson,Tommy Iliefski,Jonas Boström,Öjvind Davidsson,Ola Fjellström,Annika Björe,Christina Olsson,Johan Sundell,Ulrik Gran,Jonna Gyll,Jesper Malmberg,Olle Hidestål,Hans Emtenäs,Tor Svensson,Zhong-Qing Yuan,Gert Strandlund,Annika Åstrand,Emma Lindhardt,Gunilla Linhardt,Elin Forsström,Ågot Högberg,Frida Persson,Birgit Andersson,Anna Rönnborg,Boel Löfberg +25 more
TL;DR: In vitro structure-activity relationships from lead structure C to optimized structure 3y were described and compound 3y was found to selectively prolong the atrial effective refractory period at submicromolar concentrations.
9
Discovery of N-(1-adamantyl)-2-(4-alkylpiperazin-1-yl)acetamide derivatives as T-type calcium channel (Cav3.2) inhibitors.
Fabrizio Giordanetto,Laurent Knerr,Nidhal Selmi,Antonio Llinas,Anders Lindqvist,Qing-Dong Wang,Pernilla Ståhlberg,Fredrik Thorstensson,Victoria Ullah,Kristina Nilsson,Gavin O'Mahony,Ågot Högberg,Emma Lindhardt,Annika Åstrand,Göran Duker +14 more
TL;DR: In this paper, a HTS-based fragment hit resulted in the identification of N -(1-adamantyl)-2-[4-(2-tetrahydropyran-4-ylethyl)piperazin-1-yl]acetamide, a novel, selective T-type calcium channel (Ca v 3.2) inhibitor with in vivo antihypertensive effect in rats.
8